TTM
$6.64
YoY change
+190.7%
5Y CAGR
+21.8%
Peak year (2004)
$218.00
Latest annual
$6.54
EPS (Diluted) history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $6.54
EPS (Diluted) growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: +190.7%
EPS (Diluted) history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $6.54 | +190.7% | +$4.29 | ||
| 2024 | $2.25 | -40.9% | −$1.56 | ||
| 2023 | $3.81 | +80.6% | +$1.70 | ||
| 2022 | $2.11 | +2537.5% | +$2.03 | ||
| 2021 | $0.08 | -96.7% | −$2.36 | ||
| 2020 | $2.44 | +136.9% | +$1.41 | ||
| 2019 | $1.03 | -39.4% | −$0.67 | ||
| 2018 | $1.70 | -28.3% | −$0.67 | ||
| 2017 | $2.37 | -14.1% | −$0.39 | ||
| 2016 | $2.76 | +23.8% | +$0.53 | ||
| 2015 | $2.23 | +127.6% | +$1.25 | ||
| 2014 | $0.98 | -52.0% | −$1.06 | ||
| 2013 | $2.04 | -58.6% | −$2.89 | ||
| 2012 | $4.93 | -32.5% | −$2.37 | ||
| 2011 | $7.30 | +31.1% | +$1.73 | ||
| 2010 | $5.57 | +7.3% | +$0.38 | ||
| 2009 | $5.19 | +23.6% | +$0.99 | ||
| 2008 | $4.20 | +12.6% | +$0.47 | ||
| 2007 | $3.73 | -3.1% | −$0.12 | ||
| 2006 | $3.85 | +32.3% | +$0.94 | ||
| 2005 | $2.91 | -98.7% | −$215.09 | ||
| 2004 | $218.00 | +22.5% | +$40.00 | ||
| 2003 | $178.00 | +10753.7% | +$176.36 | ||
| 2002 | $1.64 | -0.6% | −$0.01 | ||
| 2001 | $1.65 | +15.4% | +$0.22 | ||
| 2000 | $1.43 | +123.4% | +$0.79 | ||
| 1999 | $0.64 | -56.2% | −$0.82 | ||
| 1998 | $1.46 | +15.0% | +$0.19 | ||
| 1997 | $1.27 | +9.5% | +$0.11 | ||
| 1996 | $1.16 | +110.9% | +$0.61 | ||
| 1995 | $0.55 | -24.7% | −$0.18 | ||
| 1994 | $0.73 | -2.7% | −$0.02 | ||
| 1993 | $0.75 | +341.2% | +$0.58 | ||
| 1992 | $0.17 | -81.1% | −$0.73 | ||
| 1991 | $0.90 | +50.0% | +$0.30 | ||
| 1990 | $0.60 | — | — |
- 2025$6.54+190.7%
- 2024$2.25-40.9%
- 2023$3.81+80.6%
- 2022$2.11+2537.5%
- 2021$0.08-96.7%
- 2020$2.44+136.9%
- 2019$1.03-39.4%
- 2018$1.70-28.3%
- 2017$2.37-14.1%
- 2016$2.76+23.8%
- 2015$2.23+127.6%
- 2014$0.98-52.0%
- 2013$2.04-58.6%
- 2012$4.93-32.5%
- 2011$7.30+31.1%
- 2010$5.57+7.3%
- 2009$5.19+23.6%
- 2008$4.20+12.6%
- 2007$3.73-3.1%
- 2006$3.85+32.3%
- 2005$2.91-98.7%
- 2004$218.00+22.5%
- 2003$178.00+10753.7%
- 2002$1.64-0.6%
- 2001$1.65+15.4%
- 2000$1.43+123.4%
- 1999$0.64-56.2%
- 1998$1.46+15.0%
- 1997$1.27+9.5%
- 1996$1.16+110.9%
- 1995$0.55-24.7%
- 1994$0.73-2.7%
- 1993$0.75+341.2%
- 1992$0.17-81.1%
- 1991$0.90+50.0%
- 1990$0.60—
EPS (Diluted) values are taken from AstraZeneca's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's current diluted EPS (TTM) is $6.64. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
In 2025, AstraZeneca (AZN) diluted EPS totalled $6.54 – surged 190.7% year-over-year.
AstraZeneca diluted EPS has grown on net over the period, with a +21.8% compound annual growth rate over 2020–2025 (5 years).
AstraZeneca diluted EPS plunged from $218.00 in 2004 to $6.54 in 2025, a 97.0% drawdown.
The record annual diluted EPS stands at $218.00, reached in 2004; the historical low of $0.08 was recorded in 2021.
AstraZeneca EPS (Diluted) by Year
AstraZeneca EPS (Diluted) 2025: $6.54
AstraZeneca diluted EPS in 2025 was $6.54, surged 190.7% from 2024.
AstraZeneca EPS (Diluted) 2024: $2.25
2024's diluted EPS for AstraZeneca came in at $2.25, plunged 40.9% below 2023.
AstraZeneca EPS (Diluted) 2023: $3.81
AstraZeneca posted diluted EPS of $3.81 in 2023, surged 80.6% from 2022.
AstraZeneca EPS (Diluted) 2022: $2.11
In 2022, AstraZeneca reported diluted EPS of $2.11, surged 2537.5% from 2021.
AstraZeneca EPS (Diluted) 2021: $0.08
AstraZeneca diluted EPS in 2021 was $0.08.
See more financial history for AstraZeneca (AZN). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of AstraZeneca (AZN), ranked by their latest diluted EPS
| $22.95 | |
| $17.74 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $3.59 | |
| $2.37 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $3.59
- $2.37
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation